glp 1 trump deal Eli Lilly and Novo Nordisk are lowering GLP-1 drug costs thanks to a new with President Trump. π KTSM - The Trump administration
Description
The Trump administrations recent Most Favored Nation (MFN) pricing deal, announced in November 2025, represented the first major effort to close that gap, anchoring widely discussed consumer prices around $350 per month for many injectable GLP-1 through manufacturer self-pay programs
Abstract Diabetes and obesity are growing problems worldwide and are associated with a range of acute and chronic complications, including acute myocardial infarction (AMI) and stroke
Prevention is simpler than you think
A.SaigalA.SzamosiJ
